Trust Size
$110M
Peak Price
$49.00
Current Price
$0.63
Return
-93.7%
Price Journey
What Happened
Citius Oncology is a biopharmaceutical company focused on developing anti-cancer treatments, including its lead product LYMPHIR for the treatment of cutaneous T-cell lymphoma.
Citius Oncology was spun off from Citius Pharmaceuticals and trades under CTOR. The company's LYMPHIR (denileukin diftitox) received FDA approval for the treatment of relapsed or refractory cutaneous T-cell lymphoma. Despite the FDA approval, the stock has declined and the company has reported going concern warnings as it works to commercialize the treatment.
Timeline
2022-03-08
S-1 Registration Filed
SEC Filing Details
CIK Number
1851484
Total SEC Filings
233
State of Incorporation
DE
Last Filing Date
2026-03-10
Business Location
New York, NY
Trust/Asset Size
$110M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Citius Oncology